Kidney cell carcinoma: Which patient needs immunotherapy?;NIERENZELLKARZINOM: WELCHER PATIENT BENOTIGT IMMUNTHERAPIE?

Urologe - Ausgabe B

Volumn 38, Issue SUPPL. 1, 1998, Pages

  Mickisch, G H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FLOXURIDINE; FLUOROURACIL; INTERLEUKIN 2; MITOMYCIN C; VINBLASTINE;

CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; NEPHRECTOMY; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0031956938     PISSN: 00421111     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001310050369     Document Type: Conference Paper

References (23)

1. Bennett RT, Lemer SE, Taub HC, Dutcher JP, Fleischmann J (1995) Cytoreductive surgery for stage IV renal cell carcinoma. J Uroll 54: 32-34
2. Boring CC, Squires TS, Clark CW (1996) Cancer Statistics 1996. CA: A cancer Journal for Clinicians 46: 19-38
3. Bukowsky RM (1997) Natural history and therapy of metastatic renal cell carcinoma. Cancer 80: 1198-1220
4. Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Sosman JA, Eckardt JR, Ernest ML, Doroshow J, Atkins M (1997) Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 3. 142-143
5. Fossa S, Jones M, Johnson P, Joffe J, Holdener E, Elson P, Ritchse A, Selby P (1995) Interferon-alpha and survival in renal cell cancer. Sr J Urol 76. 286-290
6. Goey SH, Verweij J, Stoter G (1996) Immunotherapy of metastatic renal cell cancer. Ann Oncol 7: 887-900
7. Haas GP, Redman BG, Rao VK, Dybal E, Pontes JE, Hilman GG (1993) Immunotherapy for metastatic renal cell cancer: effect on the primary tumor. J Immunother 13: 130-135
8. Hanninen EL, Kirchner H, Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Uroll 55: 19-25
9. Hoffmockel G, Langer W, Theiss M, Gruss A, Frohmuller HG (1996) Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J Urol 156 18-21
10. Jensen OM, Esteve J, Moller H, Renard H (1990) Cancer in the European Community and its member states. Eur J Cancer 26: 1167-1256
11. Joffe JK, Banks RE, Forbes MA, Hallam S, Jenkins A, Patel PM, Hall GD, Velikova G, Adams J, Crossley A, Johnson PWM, Whicher JT, Selby PJ (1996) A phase II study of interferon-α, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 77: 638-649
12. Mickisch GH (1994) Therapie des Nierenzellkarzinoms - Eine Aktualisierung notwendig? Akt Urol 25: 77-83
13. Mickisch GH (1994) Moderne aspecten van het niercelcardnoom. 2: 9-11
14. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE (1993) Interferon alpha-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11: 1368-1375
15. Novick AC (1995) Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renal cell carcinoma. Semin Oncol 22: 29-33
16. Rackley R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D (1994) The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 152: 1399-1403
17. Robson CJ (1963) Radical nephrectomy for renal cell carcinoma. J Urol 89: 37-42
18. Robson G, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101 297-301
19. Scheltema JMW, Mickisch GH (1997) Management of metastatic renal cell carcinoma: role of nephrectomy, immunotherapy, failure of chemotherapy and drug resistance. Europ. Urol. Update, Series 6: 27-33
20. Walpole ET, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G, Cavasotto G, Wiernik PH (1993) Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin 2. J Immunother 13: 275-281
21. Walther MM, Yang JC, Pass HI, Linehan WM, Rosen berg SA (1997) Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 158: 1675-1678
22. Wolf JS, Aronson FR, Small EJ, Carroll PR (1994) Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol 55: 7-13
23. Yagoda A, Abi-Rachel B, Petrylak D (1995) Chemotherapy for advanced renal cell carcinoma: 1983-1993. Semin Oncol 22: 42-60